Cargando…
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
In less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has evolved from a potential anti-angina drug to an on-demand oral treatment for erectile dysfunction (Viagra), and more recently to a new orally active treatment for pulmonary hypertension (Revatio). Here we...
Autores principales: | Ghofrani, Hossein A., Osterloh, Ian H., Grimminger, Friedrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097805/ https://www.ncbi.nlm.nih.gov/pubmed/16883306 http://dx.doi.org/10.1038/nrd2030 |
Ejemplares similares
-
Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study
por: Gall, Henning, et al.
Publicado: (2016) -
Mechanisms of disease: pulmonary arterial hypertension
por: Schermuly, Ralph T., et al.
Publicado: (2011) -
Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence
por: Hatzimouratidis, Konstantinos
Publicado: (2006) -
Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009) -
Hepatorenal dysfunction in patients with chronic thromboembolic pulmonary hypertension
por: Yogeswaran, Athiththan, et al.
Publicado: (2023)